事業成果物：
研究成果は、国内外の学会などに報告し、あるいは原著論文として論文発表を行った。学会発表などは省略し、英文原著論文のみを記載する。

１．Hirose S, Mashima T, Yuan X, Yamashita M, Kitano S, Torii S, Migita T, Seimiya H. Interleukin-4 induced 1-mediated resistance to an immune checkpoint inhibitor through suppression of CD8+ T cell infiltration in melanoma.
Cancer Sci., 115:791-803, 2024.
doi: 10.1111/cas.16073.

２．Morino S, Mashima T, Shirai F, Nagayama S, Katayama R, Seimiya H. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
Cancer Lett., 584:216632, 2024.
doi: 10.1016/j.canlet.2024.216632.

３．Chen M, Mashima T, Oishi T, Muramatsu Y, Seto Y, Takamatsu M, Kawata N, Morino S, Nakamura A, Inaba S, Yuan X, Maruyama K, Suzuki M, Sato A, Yoshida H, Jang MK, Mizutani A, Takeuchi K, Yamaguchi K, Shirai F, Nagayama S, Katayama R, Seimiya H. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells.
Br. J. Cancer, 130:151-162, 2024.
doi: 10.1038/s41416-023-02484-8.

４．Suzuki M, Uchibori K, Oh-Hara T, Nomura Y, Suzuki R, Takemoto A, Araki M, Matsumoto S, Sagae Y, Kukimoto-Niino M, Kawase Y, Shirouzu M, Okuno Y, Nishio M, Fujita N, Katayama R. A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer.
NPJ Precis. Onc., 8(1):46, 2024.
doi: 10.1038/s41698-024-00542-9.

５．Kondo, N., Utsumi, T., Shimizu, Y., Takemoto, A., Oh-Hara, T., Uchibori, K., Subat-Motoshi, S., Ninomiya, H., Takeuchi, K., Nishio, M., Miyazaki, Y. and Katayama, R. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
JCI Insight, 8(24):e173688, 2023.　
doi: 10.1172/jci.insight.173688.

６．Haraguchi M, Kiyotani K, Tate T, Sakata S, Sagawa R, Takagi S, Nagayama S, Takeuchi K, Takahashi K, Katayama R. Spatiotemporal commonality of the TCR repertoire in a T-cell memorymurine model and in metastatic human colorectal cancer.
Cancer Immunol Immunothera., 72(9):2971-2989, 2023.
doi: 10.1007/s00262-023-03473-9.

７．Takahashi M, Okamoto Y, Kato Y, Shirahama H, Tsukahara S, Sugimoto Y, Tomida A. Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation.
Heliyon, 9:e14799, 2023.
doi: 10.1016/j.heliyon.2023.e14799

８．Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi SI, Dan S. Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
Cell Death Dis., 14(2):169, 2023.
doi: 10.1038/s41419-023-05690-7.

９．Hanaki Y, Shikata Y, Kikumori M, Okamura M, Dan S, Imoto M, Irie K. Invivo anti-cancer activity of 10-methyl-aplog-1, a simplified analog of aplysiatoxin, and its possible signaling pathway associated with G1 arrest.
Biochem. Biophys. Res. Commun., 675:19-25, 2023.
doi: 10.1016/j.bbrc.2023.07.008.

報告書

事業成果物名	2023年度 腫瘍細胞社会ネットワークを標的とした革新的がん治療薬の開発
ファイル	形式：PDF　容量：83KB
事業成果物名	腫瘍細胞社会ネットワークを標的とした革新的がん治療薬の開発
URL	https://nippon.zaidan.info/nf_lib/nf_libServlet/nf_lib1050?np=1019&jigyo_id=0000098377